2 Valuation Signals For Extendicare (TSX:EXE) After Earnings And Dividend Update

Extendicare earnings and dividend update

Extendicare (TSX:EXE) is back in focus after reporting its second quarter and first half 2026 results on August 6, alongside confirming its monthly cash dividend for August.

The company reported second quarter sales of CA$611.04 million with net income of CA$30.85 million. For the first six months of 2026, sales were CA$1,076.26 million and net income was CA$71.58 million.

See our latest analysis for Extendicare.

Extendicare’s latest earnings and dividend update has come after a strong run, with the share price at CA$32.74 and a year to date share price return of 55.31%. The 1 year total shareholder return of 150.25% and 5 year total shareholder return of more than 4x highlight how sentiment has shifted over time.

If you are weighing Extendicare’s momentum against other opportunities in the market, it can help to broaden your watchlist with companies outside healthcare. Now is a good time to scan the 3 top founder-led companies

After a move that has taken Extendicare to CA$32.74, while analyst targets and intrinsic value estimates point to different levels, the key issue now is where fair value really sits within that spread.

Price-to-Earnings of 25.7x: Is it justified for Extendicare?

With Extendicare trading at CA$32.74, the stock is priced at a P/E of 25.7x, which sits slightly above some healthcare peers but below the broader Healthcare industry average.

The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors are paying for each dollar of profit. For a company like Extendicare, which operates in long-term care, home health care and managed services, earnings-based measures are often a primary reference point for investors assessing profitability and capital intensity.

According to the data, Extendicare is considered good value versus its peer group, with its 25.7x P/E below the peer average of 28.2x. However, it is described as expensive when compared to the North American Healthcare industry P/E of 25.3x, and the SWS DCF model suggests the share price of CA$32.74 is above an estimated future cash flow value of CA$5.72. Those mixed signals highlight that the market is paying a full price for current earnings, while the cash flow-based estimate points to a much lower level that investors may want to understand in more detail.

Against the broader Healthcare industry average P/E of 46.7x, Extendicare’s 25.7x multiple looks considerably lower, which indicates investors are not assigning the same earnings multiple seen in some other healthcare stocks. That gap can sometimes close if sentiment or growth expectations change, or it can persist if the market continues to price Extendicare differently from higher multiple healthcare companies.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 25.7x (ABOUT RIGHT)

However, Extendicare still faces risks from any pressure on funding for senior care and potential changes to demand across its long-term and home health care segments.

Find out about the key risks to this Extendicare narrative.

Another view on Extendicare’s valuation

The SWS DCF model presents a different perspective on Extendicare. While the market is currently paying a P/E of 25.7x at CA$32.74, the model indicates a future cash flow value of CA$5.72 per share, which points to a heavily overvalued stock on this measure.

This kind of gap can matter for you because it raises the question of which signal carries more weight: the earnings multiple that looks reasonable versus peers, or a cash flow estimate that sits far below the current share price. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Extendicare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 11 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of questions around Extendicare’s valuation and the split between risks and rewards, this is a moment to look closely at the details and act on your own judgement. To see both sides in one place and pressure test your view against the data, start with the 5 key rewards and 2 important warning signs

Looking for more investment ideas beyond Extendicare?

If you are reassessing Extendicare’s valuation debate, now is a smart moment to widen your opportunity set and see what else stands out on the Simply Wall St screener.

• Target higher income potential by reviewing the 4 dividend fortresses that could complement or contrast Extendicare’s profile.
• Pinpoint quality at a measured price when you scan the 11 high quality undervalued stocks that pass strict fundamental checks.
• Spot opportunities others may be missing by checking the screener containing 9 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com